Key result
NOAC use for secondary stroke prevention in AF patients was associated with a lower 30-day mortality risk after intracranial hemorrhage compared to VKAs.
Why the study?
Potential differences in the incidence, characteristics, and outcomes between intracranial haemorrhages associated with NOACs versus VKAs after treatment initiation for AF in ischaemic stroke patients were unclear.
Do NOACs reduce the risk of fatal intracranial haemorrhage compared to VKAs in AF patients receiving secondary stroke prevention?
Cohort (n=4,912)
Yes
Do NOACs reduce the risk of fatal intracranial haemorrhage compared to VKAs in AF patients receiving secondary stroke prevention?
In AF patients receiving secondary stroke prevention, intracranial hemorrhages associated with NOACs have a lower 30-day mortality risk compared to those associated with VKAs.
Answers are grounded in this paper and cite their sources.
May support preferring NOACs for secondary AF stroke prevention; leaves open causal inference from this observational meta-analysis.
BACKGROUND AND PURPOSE: In this pooled analysis of seven multicentre cohorts potential differences were investigated in the incidence, characteristics and outcomes between intracranial haemorrhages (ICHs) associated with the use of non-vitamin K antagonist oral anticoagulants (NOAC-ICH) or with vitamin K antagonists (VKA-ICH) in ischaemic stroke patients after oral anticoagulant treatment initiation for atrial fibrillation (AF). METHODS: Data from 4912 eligible AF patients who were admitted in a stroke unit with ischaemic stroke or transient ischaemic attack and who were treated with either VKAs or NOACs within 3 months post-stroke were included. Fatal ICH was defined as death occurring during the first 30 days after ICH onset. A meta-analysis of available observational studies reporting 30-day mortality rates from NOAC-ICH or VKA-ICH onset was additionally performed. RESULTS: During 5970 patient-years of follow-up 71 participants had an ICH, of whom 20 were NOAC-ICH and 51 VKA-ICH. Patients in the two groups had comparable baseline characteristics, except for the higher prevalence of kidney disease in VKA-ICH patients. There was a non-significant higher number of fatal ICH in patients with VKAs (11 events per 3385 patient-years) than in those with NOACs (three events per 2623 patient-years; hazard ratio 0.32, 95% confidence interval 0.09-1.14). Three-month functional outcomes were similar (P > 0.2) in the two groups. The meta-analysis showed a lower 30-day mortality risk for patients with NOAC-ICH compared to VKA-ICH (relative risk 0.70, 95% confidence interval 0.51-0.95). CONCLUSIONS: Non-vitamin K oral anticoagulants for intracranial haemorrhages and VKA-ICH occurring during secondary stroke prevention of AF patients have comparable baseline characteristics and outcomes except for the risk of fatal ICH within 30 days, which might be greater in VKA-ICH.
No takes yet. Share an insight, caveat, or question.
Tsivgoulis et al. (2020) conducted a cohort in Atrial fibrillation with ischaemic stroke or transient ischaemic attack (n=4,912). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Fatal intracranial haemorrhage (death occurring during the first 30 days after ICH onset) (HR 0.32, 95% CI 0.09-1.14). NOAC use for secondary stroke prevention in AF patients was associated with a lower 30-day mortality risk after intracranial hemorrhage compared to VKAs.
Synapse has enriched 10 related papers. Consider them for comparative context: